進行性黒色腫を有する成人におけるリフィルセル(腫瘍浸潤リンパ球)の研究
以前に治療を受けた進行性黒色腫の参加者を対象としたLifileucel(腫瘍浸潤リンパ球[TIL])の第2相多施設共同非盲検試験
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
調査の概要
詳細な説明
This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor
± a MEK inhibitor
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- Sarah Cannon Research Institute
-
-
-
-
-
London、イギリス、SW3 6JJ
- Royal Marsden Hospital
-
-
-
-
Queensland
-
Greenslopes、Queensland、オーストラリア、4120
- Greenslopes Private Hospital
-
-
-
-
Ontario, Canada
-
Toronto、Ontario, Canada、カナダ、M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec, Canada
-
Montral、Quebec, Canada、カナダ、H2X 0A9
- Centre Hospitalier de l'Universite de Montreal
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
- The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
- The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
- Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
- Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
- Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- Participants must have adequate organ function.
- Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion Criteria:
- Participant has melanoma of uveal/ocular origin.
- Participant has symptomatic untreated brain metastases.
- Participant has active uveitis that requires active treatment.
- Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
- Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
- Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
- Participant has a history of allogeneic cell or organ transplant.
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Other protocol defined inclusion/exclusion criteria could apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single Arm
Lifileucel |
A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate
時間枠:12 months
|
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete Response Rate
時間枠:12 months
|
To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Duration of Response
時間枠:12 months
|
To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Disease Control Rate
時間枠:12 months
|
To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Progression-Free Survival
時間枠:12 months
|
To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Overall Survival
時間枠:18 months
|
To evaluate the efficacy of lifileucel as measured by OS |
18 months
|
|
Adverse Events
時間枠:18 months
|
To demonstrate safety and tolerability of lifileucel |
18 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- IOV-MEL-202
- 2025-522054-40-00 (Ctis)
- 2025 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。